 |
|
Maximum: 1 CME cr.
Sign in to view your progression
|
Topic description:
This learning module includes an overview of hormonal therapy for women who have various sexual dysfunctions and provides insights and perspectives on data from the Women’s Health Initiative (WHI).
Video segments in the learning module:
- Video 1: Introduction to Understanding Sex Steroid Hormones
- Video 2: Menopausal Estrogen and Hormone Therapy: Understanding the Real Risks and Benefits
- Video 3:Understanding Sex Steroid Hormones: Androgens
- Video 4: Sex Steroids: Understanding Progesterone and Progestins
- Video 5: Addressing Concerns of the Menopausal Patient – Mock Interview
Faculty Information
James A. Simon, MD
IntimMedicine Specialists
Clinical Professor of Obstetrics & Gynecology
The George Washington University School of Medicine
Washington, District of Columbia, USA
Sharon J. Parish, MD
Professor of Medicine in Clinical Psychiatry and Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York, USA
Tami Rowen, MD
Assistant Professor of Obstetrics & Gynecology
University of California, San Francisco
San Francisco, California, USA
Best practice:
Health care professionals (HCPs) utilize the evidence for safety and efficacy of estrogen and progestogen therapy for menopause management and off label use of testosterone for HSDD, determining whether the benefits outweigh the risks for the patient’s individual clinical situation.
Current practice:
HCPs often do not offer hormonal therapy following the controversial results of the Women’s Health Initiative study, and patients similarly do not feel comfortable using hormonal therapy due to fears about cancer and heart disease. Since there is no FDA approved testosterone therapy for women, few HCPs prescribe testosterone presently.
Resulting gaps:
HCPs have limited knowledge of the data on risks and benefits of menopausal hormonal therapy, the important differences between oral and non-oral estrogen delivery, which progestogen(s) would fit best and why, and the full range of dosing and regimen options. HCPs are not knowledgeable about how to treat with testosterone when the risk benefit ratio for a particular patient is in favor of treatment.
Outcome indicated/Improvement in:
A thorough review of the data, risks, and benefits in different patient circumstances, presentations of the choices and options available to patients, and key discussion points will lead to improvement in the practitioner’s knowledge and ability to inform and treat patients.
Learning objectives:
(1) Apply relevant data and appropriate individual choices to the education of both HCPs and patients in order to guide them through the process of menopausal hormone therapy decision-making.
(2) Analyze the major differences in available hormone therapies to help individualize the treatment and enhance the benefits while decreasing the risks for the menopausal patient.
(3) Discuss the safety and efficacy of testosterone therapy in women, identifying the benefits and risks associated with off label testosterone use
(4) Understand the differences between various progestogens.
Medical health care practitioners (MDs, DOs, PAs, NPs, etc.) in any field (Sexual Medicine, Obstetrics & Gynecology, Internal Medicine, Family Medicine, Urology, etc.) who would like to address sexual health in caring for their female patients.
ISSWSH Learner Notification
Understanding Hormone Therapy and the Roles of Estrogen, Androgens, and Progestogens
Dr. J. Simon, Dr. S. Parish and Dr. T. Rowen
September 01, 2019 - September 01, 2021
Online
Acknowledgement of Financial Commercial Support
AMAG Pharmaceuticals, Inc.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for the Study of Women’s Sexual Health, Inc. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives - After attending this program you should be able to:
1. Apply relevant data and appropriate individual choices to the education of both HCPs and patients in order to guide them through the process of menopausal hormone therapy decision-making.
2. Analyze the major differences in available hormone therapies to help individualize the treatment and enhance the benefits while decreasing the risks for the menopausal patient.
3. Discuss the safety and efficacy of testosterone therapy in women, identifying the benefits and risks associated with off label testosterone use
4. Understand the differences between various progestogens.
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
|
First |
Last |
Commercial Interest |
|
S. |
Parish |
AMAG: Scientific/Medical Advisory Board Member, Duchesnay: Scientific/Medical Advisory Board Member, Strategic Scientific Technologies (SST): Consultant, TherapeuticsMD: Consultant, Proctor & Gamble: Consultant, AMAG: Other, Pfizer: Other, TherapeuticsMD: Other |
|
T. |
Rowen |
Genomic Health: Consultant |
|
J.A. |
Simon |
Grant/Research Support: AbbVie, Inc., Allergan, Plc, Agile Therapeutics, Bayer Healthcare LLC., Endoceutics, Inc., GTx, Inc., Ipsen, Myovant Sciences, New England Research Institute, Inc., ObsEva SA, Palatin Technologies, Symbio Research, Inc., TherapeuticsMD, Viveve Medical. Consultant/Advisory Board: AbbVie, Inc., Allergan, Plc, AMAG Pharmaceuticals, Inc., Amgen, Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises, LLC, Covance Inc., Daré Bioscience, Duchesnay USA, Hologic Inc., KaNDy/NeRRe Therapeutics Ltd., Mitsubishi Tanabe Pharma Development America, Inc., ObsEva SA, Sanofi S.A., Shionogi Inc., Sprout2, Inc., TherapeuticsMD Speakers’ Bureau: AbbVie, Inc., AMAG Pharmaceuticals, Inc., Duchesnay USA, Novo Nordisk, Shionogi Inc. Stock Shareholder: Sermonix Pharmaceuticals (direct purchase) |
|
Understanding Hormone Therapy and the Roles of Estrogen, Androgens, and Progestogens
|
|
|
Self-assessment & Certificate
|
|